Publications
Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
This activity is supported by an educational grant from AstraZeneca.
March 2022
A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis
Kidney Int. 2022;101(2):403-413 doi: 10.1016/j.kint.2021.08.027
Post-hoc analysis data suggests that the addition of belimumab to standard therapy may be effective in preserving long-term kidney function in patients with lupus nephritis (LN).
Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials
Lancet Rheumatol. Published online February 3, 2022
Across two pivotal phase 3 trials (TULIP-1 and TULIP-2), anifrolumab treatment improved systemic lupus erythematosus (SLE) disease activity across multiple organ domains, compared with placebo.
Easy-BILAG: a new tool for simplified recording of SLE disease activity using BILAG-2004 index
Rheumatology (Oxford). 2022. Epub ahead of print doi: 10.1093/rheumatology/keab883
Easy-BILAG is a high-accuracy, time-efficient tool for recording BILAG-2004 disease activity in systemic lupus erythematosus (SLE).
Disease activity measurements in SLE are necessary for optimal patient care, treat-to-target approaches and clinical guidelines. However, administrative burden and potential frequency of errors with the current comprehensive disease activity instrument (BILAG-2004) limits its use in routine practice.
February 2022
The Interferon Gene Signature as a Clinically Relevant Biomarker in Autoimmune Rheumatic Disease
Lancet Rheumatol 2022;4:e61–72.
The interferon gene signature (IGS) fits into the paradigm of a personalised approach to care in rheumatic diseases, where an individual’s score could inform either prompt diagnosis, early use of certain therapies, or presage specific clinical phenotypes.
January 2022
Efficacy and Safety of Ustekinumab in Patients with Active Systemic Lupus Erythematosus: Results Through 2 Years of an Open-Label Extension in a Phase 2 Study
J Rheumatol. 2021. Epub ahead of print
Phase II data demonstrate clinical benefit in global and organ-specific SLE-activity measures with ustekinumab through 2 years with no new or unexpected safety findings.
Treatment of refractory subacute cutaneous lupus erythematosus with baricitinib
Clin Exp Dermatol. 2021. Epub ahead of print
Phase II data and two individual case reports have shown significant improvement in signs and symptoms of disease in patients with systemic lupus erythematosus (SLE) receiving baricitinib. This case study by Joos et al. reports a further patient with SLE treated successfully with baricitinib.
November 2021
Efficacy, Safety, and Pharmacodynamic Effects of the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial
Arthritis Rheumatol. 2021;73(10):183–46
Despite evidence of strong pathway inhibition, findings from a Phase 2 study of patients with moderate-to-severe SLE indicate that fenebrutinib did not demonstrate a treatment benefit over placebo.
Keywords:
What Are The Benefits And Harms Of Belimumab For Patients With Systemic Lupus Erythematosus?: A Cochrane Review Summary With Commentary
Int J Rheum Dis. 2021;24(10):1331–3
Biologic therapies, particularly belimumab, show promising results in the clinical management of SLE.
B-cell Depletion With Obinutuzumab for the Treatment of Proliferative Lupus Nephritis: A Randomised, Double-blind, Placebo-controlled Trial
Ann Rheum Dis. 2021. doi:10.1136/annrheumdis-2021-220920
Phase 2 study data support the use of obinutuzumab in proliferative lupus nephritis (LN) being further evaluated in a global Phase 3 study.
October 2021
Two-Year, Randomised, Controlled Trial of Belimumab in Lupus Nephritis
N Engl J Med. 2020;383(12):1117–28.
LN occurs in 25–60% of patients with SLE. However, patients with LN are often excluded from clinical trials of SLE therapies.